Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06136598Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event at 20 months, Number of Participants Who Discontinue Study Intervention Due to an Adverse Event at 20 months and 6 more. Started Jan 2024; status: completed.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06136598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136598.